• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Beyond Bias: Aggregate Approaches to Conflicts of Interest Research and Policy in Biomedical Research.超越偏见:生物医学研究中利益冲突研究与政策的综合方法
World Med Health Policy. 2024 Sep;16(3):489-505. doi: 10.1002/wmh3.608. Epub 2024 Apr 15.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
4
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.成年自闭症患者的就业生活经历:系统检索与综述
Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec.
5
Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs).制定基于证据的指南,用于在患者信息单页/说明书(PrinciPILs)中描述潜在益处和危害,这些信息单页既能提供信息又不会造成伤害。
Health Technol Assess. 2025 Aug;29(43):1-20. doi: 10.3310/GJJH2402.
6
Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review.解决生物医学研究中资金偏见和利益冲突的政策机制研究:一项范围综述
Res Integr Peer Rev. 2025 May 14;10(1):6. doi: 10.1186/s41073-025-00164-0.
7
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.医疗专业人员在急症医院环境中团队合作教育的经验:对定性文献的系统综述
JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843.
8
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
9
Understanding "interests": historical insights for managing conflicts of interest in healthcare and biomedical science.理解“利益”:关于管理医疗保健和生物医学科学中利益冲突的历史见解
Med Health Care Philos. 2025 Sep;28(3):623-638. doi: 10.1007/s11019-025-10268-5. Epub 2025 Apr 22.
10
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.

引用本文的文献

1
Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review.解决生物医学研究中资金偏见和利益冲突的政策机制研究:一项范围综述
Res Integr Peer Rev. 2025 May 14;10(1):6. doi: 10.1186/s41073-025-00164-0.

本文引用的文献

1
Disclosing and Managing Non-Financial Conflicts of Interest in Scientific Publications.科学出版物中利益冲突的披露与管理:非财务利益冲突
Res Ethics. 2023 Apr;19(2):121-138. doi: 10.1177/17470161221148387. Epub 2023 Jan 12.
2
Challenges of Assessing Disclosure Accuracy-All We Have Is Our Integrity.评估披露准确性的挑战——我们所拥有的只有我们的诚信。
JAMA Ophthalmol. 2023 Apr 1;141(4):383-384. doi: 10.1001/jamaophthalmol.2023.0398.
3
Harm Reduction Ethics, Public Health, and the Manufacture of Doubt.减少伤害的伦理、公共卫生与质疑的制造
Am J Bioeth. 2022 Oct;22(10):18-20. doi: 10.1080/15265161.2022.2110989.
4
Evidence for stratified conflicts of interest policies in research contexts: a methodological review.有分层利益冲突政策的研究证据:方法学综述。
BMJ Open. 2022 Sep 19;12(9):e063501. doi: 10.1136/bmjopen-2022-063501.
5
Associations Between Aggregate NLP-Extracted Conflicts of Interest and Adverse Events by Drug Product.药物产品的整体 NLP 提取利益冲突与不良事件之间的关联。
Stud Health Technol Inform. 2022 Jun 6;290:405-409. doi: 10.3233/SHTI220106.
6
The medicalization of freedom: how anti-science movements use the language of personal liberty and how we can address it.自由的医学化:反科学运动如何运用个人自由的语言以及我们应如何应对
Nat Med. 2022 Feb;28(2):219. doi: 10.1038/s41591-021-01640-y.
7
Industry-Sponsored Speaker Programs-End of the Line?行业赞助的演讲项目——走到尽头了吗?
JAMA. 2021 May 11;325(18):1835-1836. doi: 10.1001/jama.2020.26580.
8
Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform.十年后:对美国医学研究所2009年关于利益冲突及进一步改革解决方案的报告的回顾
BMJ Evid Based Med. 2022 Feb;27(1):46-54. doi: 10.1136/bmjebm-2020-111503. Epub 2020 Nov 11.
9
The Persisting Importance of Rhetoric and Equity in Health Policy and Outcomes.修辞与公平在卫生政策及成果中的持续重要性
World Med Health Policy. 2020 Jun;12(2):86-89. doi: 10.1002/wmh3.344. Epub 2020 Jun 24.
10
An overview of the commercial determinants of health.商业健康决定因素概述。
Global Health. 2020 Aug 17;16(1):74. doi: 10.1186/s12992-020-00607-x.

超越偏见:生物医学研究中利益冲突研究与政策的综合方法

Beyond Bias: Aggregate Approaches to Conflicts of Interest Research and Policy in Biomedical Research.

作者信息

Graham S Scott, Harrison Kimberlyn R, Edward Jade C Shiva, Majdik Zoltan P, Barbour Joshua B, Rousseau Justin F

机构信息

Department of Rhetoric and Writing, Center for Health Communication, The University of Texas at Austin, Austin, TX, USA.

Department of English, The University of Texas at Austin, Austin, TX, USA.

出版信息

World Med Health Policy. 2024 Sep;16(3):489-505. doi: 10.1002/wmh3.608. Epub 2024 Apr 15.

DOI:10.1002/wmh3.608
PMID:39430118
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11486516/
Abstract

Considerable efforts have been devoted to addressing the problem of conflicts of interest (COI) in health research, policy, education, and practice. An overwhelming body of evidence demonstrates that conflicts associate with deleterious outcomes for the biomedical research enterprise. Nevertheless, little has changed for research, specifically, since the Institute of Medicine's landmark was published over a decade ago. In this article, we draw on interdisciplinary research on manufactured controversies in science-policy deliberation to argue that the development of meaningful COI policy has been stymied through argumentative "wedges" designed to delay consensus and policy formation. Argumentative wedges disrupt policy formation by mischaracterizing the evidence base, continuously redefining the terms of the debate and/or recommending overly narrow criteria for who should be allowed to participate in policy deliberation. In this article, we argue researchers and policymakers interested in better addressing the harmful effects of COI can improve their efforts through strategic efforts designed to disrupt the wedges of manufactured controversy. Additionally, we argue that efforts to address COI can be further enhanced through embracing a broader framework for COI inquiry. Specifically, we argue that aggregate approaches to COI can help to disrupt these wedges and provide a strong foundation for future policy.

摘要

为解决健康研究、政策、教育及实践中的利益冲突(COI)问题,人们付出了巨大努力。大量证据表明,利益冲突与生物医学研究事业的有害后果相关。然而,自医学研究所十多年前发表具有里程碑意义的报告以来,研究领域特别是几乎没有什么变化。在本文中,我们借鉴科学政策审议中关于人为制造争议的跨学科研究,认为有意义的利益冲突政策的制定因旨在拖延共识和政策形成的论证“楔子”而受阻。论证楔子通过错误描述证据基础、不断重新定义辩论条件和/或推荐过于狭窄的参与政策审议人员标准来扰乱政策形成。在本文中,我们认为,对更好地应对利益冲突有害影响感兴趣的研究人员和政策制定者可以通过旨在打破人为制造争议楔子的战略努力来改进工作。此外,我们认为,通过采用更广泛的利益冲突调查框架,可以进一步加强应对利益冲突的努力。具体而言,我们认为利益冲突的总体方法有助于打破这些楔子,并为未来政策提供坚实基础。